Search

Your search keyword '"Geertsen, Svend S."' showing total 28 results
Start Over Author "Geertsen, Svend S."
28 results on '"Geertsen, Svend S."'

7. Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial

Author

Kuhle, Jens, primary, Chitnis, Tanuja, additional, Banwell, Brenda, additional, Tardieu, Marc, additional, Arnold, Douglas L, additional, Rawlings, Andreea M, additional, Geertsen, Svend S, additional, Lublin, Alex L, additional, Saubadu, Stephane, additional, Truffinet, Philippe, additional, and Kappos, Ludwig, additional

Published
2023
Full Text
View/download PDF

8. sj-docx-1-msj-10.1177_13524585221144742 – Supplemental material for Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial

Author

Kuhle, Jens, Chitnis, Tanuja, Banwell, Brenda, Tardieu, Marc, Arnold, Douglas L, Rawlings, Andreea M, Geertsen, Svend S, Lublin, Alex L, Saubadu, Stephane, Truffinet, Philippe, and Kappos, Ludwig

Subjects
FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-docx-1-msj-10.1177_13524585221144742 for Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial by Jens Kuhle, Tanuja Chitnis, Brenda Banwell, Marc Tardieu, Douglas L Arnold, Andreea M Rawlings, Svend S Geertsen, Alex L Lublin, Stephane Saubadu, Philippe Truffinet and Ludwig Kappos in Multiple Sclerosis Journal

Published
2023
Full Text
View/download PDF

16. Transcutaneous spinal direct current stimulation increases corticospinal transmission and enhances voluntary motor output in humans

Author

Yamaguchi, Tomofumi, primary, Beck, Mikkel M., additional, Therkildsen, Eva R., additional, Svane, Christian, additional, Forman, Christian, additional, Lorentzen, Jakob, additional, Conway, Bernard A., additional, Lundbye‐Jensen, Jesper, additional, Geertsen, Svend S., additional, and Nielsen, Jens B., additional

Published
2020
Full Text
View/download PDF

21. Short-latency crossed responses in the human biceps femoris muscle

Author

Stevenson, Andrew James Thomas, Kamavuako, Ernest Nlandu, Geertsen, Svend S., Farina, Dario, and Mrachacz-Kersting, Natalie

Abstract

Interlimb reflexes contribute to the central neural coordination between different limbs in both humans and animals. Although commissural interneurons have only been directly identified in animals, spinally mediated interlimb reflexes have been discovered in a number of human lower limb muscles, indicating their existence in humans. The aim of the present study was to investigate whether short-latency crossed-spinal reflexes are present in the contralateral biceps femoris (cBF) muscle following ipsilateral knee (iKnee) joint rotations during a sitting task, where participants maintained a slight pre-contraction in the cBF. Following iKnee extension joint rotations, an inhibitory reflex was observed in the surface electromyographic (EMG) activity of the cBF, while a facilitatory reflex was observed in the cBF following iKnee flexion joint rotations. The onset latency of both cBF reflexes was 44 ms, which is too fast for a transcortical pathway to contribute. The cBF inhibitory and facilitatory reflexes followed the automatic gain control principle, with the size of the response increasing as the level of background pre-contraction in the cBF muscle increased. In addition to the surface EMG, both short-latency inhibitory and facilitatory cBF reflexes were recorded directly at the motor unit level by intramuscular EMG, and the same population of cBF motor units that were inhibited following iKnee extension joint rotations were facilitated following iKnee flexion joint rotations. Therefore, parallel interneuronal pathways (likely involving commissural interneurons) from ipsilateral afferents to common motoneurons in the contralateral leg can likely explain the perturbation direction-dependent reversal in the sign of the short-latency cBF reflex.

Published
2015

26. In vitroevaluation of the activity of teriflunomide against SARS-CoV-2 and the human coronaviruses 229E and OC43

Author

Lang, Paul, Geertsen, Svend S., Lublin, Alex L., Potter, Michelle C., Gladysheva, Tatiana, Gregory, Jill S., and Rufi, Pascal

Abstract

Previous data have suggested an antiviral effect of teriflunomide, including against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the agent underlying the ongoing COVID-19 pandemic. We undertook an in vitroinvestigation to evaluate the inhibitory activity of teriflunomide against SARS-CoV-2 in a cell-based assay. Teriflunomide was added to Vero (kidney epithelial) cells that had been infected with SARS-CoV-2. A nucleocapsid immunofluorescence assay was performed to examine viral inhibition with teriflunomide and any potential cytotoxic effect. The 50% effective concentration (EC50) for teriflunomide against SARS-CoV-2 was 15.22 μM. No cytotoxicity was evident for teriflunomide in the Vero cells (i.e., the 50% cytotoxic concentration [CC50] was greater than the highest test concentration of 100 μM). The data were supported by additional experiments using other coronaviruses and human cell lines. In the SARS-CoV-2-infected Vero cells, the prodrug leflunomide had an EC50of 16.49 μM and a CC50of 54.80 μM. Our finding of teriflunomide-mediated inhibition of SARS-CoV-2 infection at double-digit micromolar potency adds to a growing body of evidence for a broad-ranging antiviral effect of teriflunomide.

Published
2023
Full Text
View/download PDF

28. Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.

Author

Kuhle J, Chitnis T, Banwell B, Tardieu M, Arnold DL, Rawlings AM, Geertsen SS, Lublin AL, Saubadu S, Truffinet P, and Kappos L

Subjects
Adult, Humans, Female, Child, Adolescent, Male, Intermediate Filaments, Crotonates therapeutic use, Toluidines therapeutic use, Multiple Sclerosis, Relapsing-Remitting drug therapy, Multiple Sclerosis drug therapy
Abstract

Background: The phase 3 TERIKIDS study demonstrated efficacy and manageable safety for teriflunomide versus placebo in children with relapsing multiple sclerosis (RMS)., Objective: Evaluate plasma neurofilament light chain (pNfL) concentrations in TERIKIDS., Methods: Patients received placebo or teriflunomide (14 mg adult equivalent) for up to 96 weeks in the double-blind (DB) period. In the open-label extension (OLE), all patients received teriflunomide until up to 192 weeks after randomization. pNfL was measured using single-molecule array assay (Simoa ® NF-light ™ )., Results: Baseline mean age was 14.5 years; 69.4% were female. Baseline geometric least square mean pNfL levels were similar for teriflunomide ( n  = 78) and placebo ( n  = 33) patients (19.83 vs 18.30 pg/mL). Over the combined DB and OLE periods, pNfL values were lower for teriflunomide versus placebo (analysis of variance p  < 0.01; Week 192: 10.61 vs 17.32 pg/mL). Observed between-group pNfL differences were attenuated upon adjustment for gadolinium (Gd)-enhancing or new/enlarged T2 lesion counts at DB Week 24. Higher baseline pNfL levels were associated with shorter time since first MS symptom onset, higher baseline Gd-enhancing lesion counts and T2 lesion volume, and increased hazard of high magnetic resonance imaging activity or clinical relapse during the DB period., Conclusion: Teriflunomide treatment was associated with significantly reduced pNfL levels in children with RMS., Clinicaltrials.gov Identifier: NCT02201108.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results